Amgen (AMGN) Has the Best Pipeline in Biotech, Piper Jaffray Says

April 25, 2014 7:38 AM

Piper Jaffray analyst Joshua E. Schimmer, MD reiterated an Overweight rating and $143 price target on Amgen (NASDAQ: AMGN) Friday ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found